News June 02, 2021 Preclinical Studies From Vaxxas and Collaborators Reveal Potential of Vaxxas' Novel High-Density Microarray Patch (HD-MAP) to Effectively Deliver SARS-CoV-2 Spike Vaccine October 05, 2020 Vaxxas Announces $22 Million Award from U.S. Government to Advance Vaxxas Needle-Free HD-MAP™ Vaccine Patch Technology for Pandemic Response May 28, 2020 Vaxxas Announces That Merck Exercises Option to Apply Novel Immune System Activation Platform for Vaccine Candidate May 28, 2020 Vaxxas Announces That MSD Exercises Option to Apply Novel Immune System Activation Platform for Vaccine Candidate May 28, 2020 Harro Höfliger and Vaxxas Announce Alliance to Develop Industrial-scale Aseptic Processing Line for Vaccine Products Based on Vaxxas High Density Microarray Patch (HD-MAP) March 17, 2020 Vaxxas Publication in PLoS Medicine Reveals Groundbreaking Clinical Research on Broad Potential of Novel High-Density Microarray Patch (HD-MAP) to Effeciently Deliver Vaccines Directly to the Skin, Enhancing Immunogenicity March 17, 2020 Vaxxas Awarded US$5 million [AU$7.5 million] Grant for Clinical Study of Measles and Rubella Vaccination using Vaxxas' High Density Micro-Array Patch February 09, 2015 Vaxxas Raises A$25 Million [US$20 Million] in Series B Venture Financing to Accelerate Commercialization of Novel Vaccine Platform September 15, 2014 Vaxxas Initiates Research Project on Advancing Next Generation Technology for Polio Vaccine Delivery August 26, 2014 Vaxxas Selected as World Economic Forum Technology Pioneer 2015 October 09, 2012 Vaxxas Initiates Program With Merck to Optimize Delivery of Next Generation Vaccines Utilizing Novel Mechanism for Immune System Activation October 09, 2012 Vaxxas Appoints David Hoey as Company's First CEO
